Memphasys Ltd (MEM):製品パイプライン分析

【英語タイトル】Memphasys Ltd (MEM) - Product Pipeline Analysis, 2017 Update

Single UserUSD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD1,500 ⇒換算¥163,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD2,250 ⇒換算¥245,250見積依頼/購入/質問フォーム

Memphasys Ltd (Memphasys), formerly Nusep Holdings Ltd is a bio-separations company that develops and commercializes separation techniques based on its membrane technology. The company develops felix, a non-DNA damaging lab instrument for sperm separation that separates sperm from semen sample using electrophoresis and specialist membranes for the use in fertility treatments, including IVF for humans, artificial reproductive techniques for animals; and hydrogel membranes. It caters to therapeutic plasma, IVF clinical, and research consumables markets. Memphasys also develops polymer membrane separation technology using polyacrylamide hydrogel membranes with electrophoresis. The company has operations in Australia, Singapore and the US. Memphasys is headquartered in Sydney, New South Wales, Australia.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.


- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Memphasys Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company


Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Memphasys Ltd Company Overview 4
Memphasys Ltd Company Snapshot 4
Memphasys Ltd Pipeline Products and Ongoing Clinical Trials Overview 4
Memphasys Ltd – Pipeline Analysis Overview 7
Memphasys Ltd – Key Facts 7
Memphasys Ltd – Major Products and Services 8
Memphasys Ltd Pipeline Products by Development Stage 9
Memphasys Ltd Pipeline Products Overview 11
Felix 11
Felix Product Overview 11
Second Generation Clinical SpermSep Device 12
Second Generation Clinical SpermSep Device Product Overview 12
SpermSep200 13
SpermSep200 Product Overview 13
Memphasys Ltd – Key Competitors 14
Memphasys Ltd – Key Employees 15
Memphasys Ltd – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Memphasys Ltd, Recent Developments 17
Jun 29, 2017: Memphasys: Update On Spermsep Development 17
May 18, 2017: Memphasys Provides Update On Next Stage Of SPERMSEP Development 17
Aug 10, 2015: Start Of In-Vitro Clinical Trial At Monash IVF 18
Nov 29, 2013: NuSep Board Changes 19
Oct 29, 2013: NuSep Announces Board Changes 19
Sep 06, 2013: NuSep Presents at Bioplasma Conference 20
Aug 30, 2013: NuSep announces 30 June 2013 Full Year Results 20
Jun 24, 2013: NuSep To Relocate Headquarters To Homebush, New South Wales 21
May 23, 2013: NuSep Files Patents For Development Of Diagnostic And Therapeutic For Treatment Of Dengue Using PrIME Technology 21
Nov 12, 2012: NuSep Gets TGA Accreditation For Manufacturing Of In-Vitro Diagnostics Medical Devices 22
Appendix 23
Methodology 23
About GlobalData 25
Contact Us 25
Disclaimer 26

List of Tables
Memphasys Ltd Pipeline Products and Ongoing Clinical Trials Overview 4
Memphasys Ltd Pipeline Products by Equipment Type 5
Memphasys Ltd Pipeline Products by Indication 6
Memphasys Ltd, Key Facts 7
Memphasys Ltd, Major Products and Services 8
Memphasys Ltd Number of Pipeline Products by Development Stage 9
Memphasys Ltd Pipeline Products Summary by Development Stage 10
Felix - Product Status 11
Felix - Product Description 11
Second Generation Clinical SpermSep Device - Product Status 12
Second Generation Clinical SpermSep Device - Product Description 12
SpermSep200 - Product Status 13
SpermSep200 - Product Description 13
Memphasys Ltd, Key Employees 15
Glossary 24

★調査レポート[Memphasys Ltd (MEM):製品パイプライン分析] (コード:DATA8010071)販売に関する免責事項を必ずご確認ください。
★調査レポート[Memphasys Ltd (MEM):製品パイプライン分析]についてメールでお問い合わせ